Cowen and Company reiterated their outperform rating on shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) in a research report sent to investors on Saturday. The brokerage currently has a $100.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $150.00.
Several other equities research analysts have also commented on ALNY. Credit Suisse Group AG restated a buy rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Leerink Swann restated a buy rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Zacks Investment Research lowered shares of Alnylam Pharmaceuticals from a hold rating to a sell rating in a research note on Monday, June 27th. FBR & Co reiterated a buy rating on shares of Alnylam Pharmaceuticals in a research note on Friday, June 10th. Finally, Chardan Capital reiterated a buy rating on shares of Alnylam Pharmaceuticals in a research note on Monday, July 11th. Eight research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Alnylam Pharmaceuticals has a consensus rating of Buy and a consensus price target of $80.88.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 34.27 on Friday. Alnylam Pharmaceuticals has a 1-year low of $33.16 and a 1-year high of $110.75. The stock’s market cap is $2.94 billion. The company has a 50-day moving average price of $70.69 and a 200-day moving average price of $66.05.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The company had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.09 million. During the same quarter last year, the business earned ($0.85) earnings per share. Alnylam Pharmaceuticals’s revenue was up .2% compared to the same quarter last year. On average, equities analysts expect that Alnylam Pharmaceuticals will post ($4.68) earnings per share for the current fiscal year.
In related news, CEO John Maraganore sold 30,151 shares of the firm’s stock in a transaction that occurred on Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total value of $1,950,468.19. Following the completion of the transaction, the chief executive officer now owns 148,465 shares of the company’s stock, valued at approximately $9,604,200.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.00% of the stock is currently owned by corporate insiders.
Institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP raised its position in Alnylam Pharmaceuticals by 12.1% in the first quarter. Wellington Management Group LLP now owns 11,945,607 shares of the biopharmaceutical company’s stock worth $749,826,000 after buying an additional 1,288,123 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 3.5% in the second quarter. Vanguard Group Inc. now owns 5,385,509 shares of the biopharmaceutical company’s stock worth $298,843,000 after buying an additional 182,614 shares during the period. Baillie Gifford & Co. raised its stake in shares of Alnylam Pharmaceuticals by 0.3% in the second quarter. Baillie Gifford & Co. now owns 3,390,252 shares of the biopharmaceutical company’s stock worth $188,125,000 after buying an additional 10,317 shares during the period. Dodge & Cox bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $139,650,000. Finally, State Street Corp raised its stake in shares of Alnylam Pharmaceuticals by 13.4% in the second quarter. State Street Corp now owns 2,195,504 shares of the biopharmaceutical company’s stock worth $121,832,000 after buying an additional 258,984 shares during the period. 85.96% of the stock is owned by hedge funds and other institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.